Chemotherapy treatment for the elderly patient with cancer;Manejo quimioterápico en el patiente geriátrico

Revisiones en Cancer

Volumn 21, Issue 5, 2007, Pages 232-244

  Lopez Gomez M ^a   Colmenarejo Rubio, Antonio ^b  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b HOSPITAL CENTRAL DE LA DEFENSA GÓMEZ ULLA   (Spain)

Author keywords

Chemotherapy; Old age; Physiological changes; Support treatment; Toxicity

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; LEVAMISOLE; NAVELBINE; PACLITAXEL; PLACEBO;

ANEMIA; ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CARDIOTOXICITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMORBIDITY; DIGESTIVE SYSTEM CANCER; GASTROINTESTINAL TOXICITY; GERIATRIC PATIENT; GYNECOLOGIC CANCER; HUMAN; INFECTION; LIFE EXPECTANCY; LUNG CANCER; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYELOID LEUKEMIA; NEPHROTOXICITY; NEUROTOXICITY; NONHODGKIN LYMPHOMA; OVARY CANCER; PATHOPHYSIOLOGY; POPULATION; REVIEW; SENESCENCE; TREATMENT PLANNING;

EID: 37849025772     PISSN: 02138573     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (101)

1. Quinn MJ, et al. Annals of Oncology 2003; 14: 1148-52.
2. Yancik RM, Ries LA. Cancer in the older person: Magnitude of the problem and efforts to advance the aging cancer research interface. In: Balducci L, Lyman GH, Ershler WB Extermann M. editors. Comprehensive Geriatric Oncology, London and New York: Taylor and Francis; 2004. p. 38-46.
3. LaVecchia C, Lucchini F, Negri E, et al. Cancer mortality in the elderly. In: Balducci L, Lyman GH, Ershler WB, Extermann M, editors. Comprehensive Geriatric Oncology, London and New York: Taylor and Francis; 2004. p. 29-38.
4. Anisimov A. Aging as a risk factor in multistate carcinongenesis. In: Balducci L, Lyman GH, Ershler WB, Extreman M, editors. Comprehensive geriatric oncology. London and New Cork: Taylor and Francis; 2004; p. 75-101.
5. Fernández Pol A. Growth factors, oncogenes and aging. In: Balducci L, Lyman GH, Ershler WB, Extreman M, editors. Comprehensive geriatric oncology. London and New Cork: Taylor and Francis; 2004; p. 102-26.
6. Collins K. Mammalian telomerase. Crr Opinión Cell Biol 200; 12: 378-83.
7. Rudd GN, Hartley GA, Souhani RL. Persistente of cispatin induced interstrand crosslinking in peripheral blood mononuclear cells from elderly and younger individuals. Cancer Chemother Pharmacol 1995; 35: 323-6.
8. Grune T, Jung T, Merker K, et al. Decreased proteolysis caused by protein aggregates, inclusion bodies plaques, lipofuscin, ceroid and aggrsomes during oxidative stress, aging and disease. Int J Biochem Cell Biol 2004; 36: 2519-30.
9. Hornsby P. Proliferative senescence and age. In: BAlducci L, Extermann M, editors. Biologic basis of geriatric oncology, New York Springer, in press. p. 53-73.
10. Campisi J. Proliferative senescence and cancer. In: Balducci L, Lyman GH, Ershler WB, Extermann M, editors. Comprehensive geriatric oncology: London and New York: Taylor and Francis; 2004. p. 127-37.
11. Iqbal J, Sanger W, Horman DE, et al. Bcl 2 translocation defines a unique tumour subset within the Germinal Center B-cell like diffuse large B-cell lymphoma. Am J Pathol 2004; 165; 159-66.
12. Cohen HJ, Harris T, Pieper CF. Coagulation and activation of inflammatory pathways in the development of functional decline and mortality in the elderly. Am J Med 2003; 114; 180-7.
13. Duthie E. Physiology of aging relevance to symptom perception and treatment tolerance. In: Balducci L, Lyman GH, Ershler WB, Extermann M, editors. Comprehensive geriatric oncology. London and New York: Taylor and Francis; 2004. p. 207-22.
14. Rothstein G. Disordered hematopoiesis and myelodysplasia in the elderly. J Am Ger Soc 2003; 52 (3 Supl. 2): 22-6.
15. Ferrario E, Ferrari L, Bidoli P, et al. Treatment of cancer related anaemia with epoietin. A review. Cancer treatment Rev 2004; 30: 563-75.
16. Atillasoy E, Holt PR. Gastrointestinal proliferation and aging. J Gerontol 1993; 48: B43-9.
17. Wallace S, Whiting B. Factor affecting drug binding in plasma of elderly patients. BR J Clin Pharmacol 1976; 3: 327-30.
18. Danziger RS, Tobin JD, Becker LC, et al. Teh age associated decline in glomerular filtration in healthy normotensive volunteers: lack of relationship to cardiovascular performance. J Am Geratr Soc 1990; 38 1: 127-1. 132
19. DeSanto NG, Anastasio P, Copoola S, et al. Age related changes in renal reserve and renal tubular function in healthy humans. Child Nephrol Urol 1991; 11: 33-40.
20. Yancik RM, Ries LA. Cancer in older persons: An international Golberger AL. Amaral LA, Hausdorff JM, et al. Fractal dynamics in physiology alterations with disease and aging. Pro Natl Acad Sci USA 2002; 99 (Supl. 1): 2466-74.
21. Duthie E. Physiology of aging: Relevance to symptom perception and treatment tolerance. In: Balducci L, Lyman GH, Ershler WB, Extermann M, editors. Comprehensive Geriatric Oncology. London and New York. Taylor and Francis; 2004. p. 207-22.
22. Gralla RAJ, Osoba D, Kris MG, et al. Recommendations for the use of antiemetics: Evidence-based, clinical practice guidelines. J Clin Oncol 1999; 17: 2971-94.
23. Jacobson SD, Cha S, Sargent DJ, et al. Tolerabiliy dose intensity and benefit of 5FU based chemotherapy for advanced colorectal cancer (CRC) in the elderly. A North Central Cancer Treatment Group Study. Proc Am Soc Clin Oncol 2001; 20: 384a abstr 1534.
24. Spielberger RT, Stiff P, Emmanouilides C, et al. Efficacy of Recombinant Human Keratinocyte Growth Factor (rHuKGF)in reducing Mucositis in patients with hematologic malignancies undergoing autologous peripheral blood progenitor cell transplantation after radiation based condiotioning. Results of a phase 2 trial. Proc Am Soc Clin Oncol 2001; 20; 7a abstr.
25. Balducci L, Carreca L. Oral chemotherapy of cancer in the elderly. Am J Cancer 2002; 1; 101-8.
26. Savarese DM, Savy G, Vahdat L, et al. Prevention of chemotherapy and radiation toxicity with Glutamine. Cancer Treatment Reviews 2003; 29: 501-13.
27. Popper H. Aging and the liver. Prog Liver Dis 1986; 8: 659-683/
28. Woodhouse KW, Wynne HA. Age related changes in liver sie hand hepatic blood flor: the influence on drug metabolism in the elderly. Clin Pharmacokinet 1998; 15: 287-94.
29. Cova D, Balducci L. In: Balducci L, Lyman GH, Ershler WH, Extreman M, editors. Cancer chemotherapy in the older patient. Lonon and New York: Taylor and Francis; 2004. p. 463-88.
30. Mc Pherson CP, Swenson KK, Lee MW. The effects of mammographic detection and comorbidity on the survival of older women with breast cancer. JAm Ger Soci 2002; 50: 1061-8.
31. Olison RD, Mushlin PS. Doxorubicin cardiotoxicity: Analysis of prevailing hypotheses. FASEB J 1990; 4: 3076-86.
32. Hudis C, Seidman A, Paton V, et al. Characterization of cardiac dysfunction observed in the Herceptint (trastuzumab) clinical trial. [abstract]. Breast cancer research treatment 1998; 50: 232 abstract 24.
33. Hequet O, Le QH, Moullet I, et al. Sub clinincal late cardiomyopathy after doxorubicin therapy for lymphoma in adults. J Clin Oncol 2004; 22: 1864-71.
34. Hussein M. Pegylated liposomal doxorubicin, vincristine and reduced dose dexamethasone as treatment for multiple myeloma Clin Lymphoma 2003; 4 (1S): 22-8.
35. Cova D, Balducci L. In: Balducci L, Lyman GH Ershler WH, Extermann M, editors. Cancer chemotherapy in the older patient. London and New York: Taylor and Francis; 2004. p. 463-88.
36. Mosseri M, Fingert HJ, Varticowski L, et al. In vitro evidence that mycardial ischemia resulting form 5-fluorouracil chemogherapy is due to portein kinase. C mediated vasoconstriction of vascular smoothe muscle. Cancer Res 1993; 53: 3028-33.
37. Lipschitz DA. Age related declines in hematopoietic reserve capaciy. Semin Oncol 1995; 22 (Supl. 1) 3: 5.
38. Vose JM. Cytokine use in the older patient. Semi Oncol 1995; 22 (Supl. 1): 6-8.
39. Word WC, Budman DR, Korzun AH, et al. Dose and dose intensity of adyuvante chemotherapy for stage II node positive breast carcinoma. N Eng J Med 1994; 330: 1253-9.
40. Gelman RS, Taylor SG N. Cyclophosphamide, methotrexate an 5 fluorouracil chemotherapy in women more than 65 years old with adevanced breast cancer: The elimination of age trenes in toxicity by using doses based on creatininte clearance. J Clin Oncol 1984; 2: 1404-13.
41. Shank WA JR, Balducci L. Recombinant hemopoietic growth factors: comparative hemopoietic respondse in younger and older subjects. J Am Geriatr Soc 1992; 40: 151-4.
42. Chatta GS, Price TH, Alen RC, et al. Effects of in vivo reombiant methionyl human grnaulociyte colony stimulating faco on the neutrophil response and peripheral blood colony forming cells in ghealyt young and elderly adult volunteers. Blood 1994; 84: 2923-9.
43. Ratain MJ, Schilsky RL, Choi KE, et al. Adaptive control of etoposide administratin: Impact of interpatient pharmacodynamic variability. Clin Pharmacol Ther 1989; 45: 226-33.
44. Dixon DO, Neilan B, Jones SE, et al. Effecto of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: The Southwest Oncology Group experience. Clin Oncol 1986; 4; 295-305.
45. Meyer RM, Browman GP, Sarnosh ML, et al. Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with Non Hodgkin's Lymphoma. J Clin Oncol 1995; 13: 2386-93.
46. Valagussa P, Bonadonna G. Breast cancer. Cancer Chemother Biol Resp Modif 2002; 20: 493-517.
47. Wood WC, Budman DR, Korzun AH, et al. Dose and dose intensity of adjuvant chemotherapy for Stage II positive breast carcinoma. N Engl J Med 1994; 330 (18): 1253-9.
48. Jernal A, Thomas A, Taylor M, Thun M. Cancer statistics 2001. Ca Cancer J Clin 2002; 52: 23-47.
49. Yancik R. Cancer burden in the aged: An epidemiologic and demographic overview. Cancer 1997; 80: 1273-83.
50. Early Breast Cancer Trialists Collaborative Group. Polychemotherapy for early breast cancer: An overview of therandomised trials. Lancet 1998; 352: 930-42.
51. Goldhirsch A, Clic JH, Gelber RD, et al. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. J Natl Cancer Ins 1998; 90: 1601-8.
52. O'Reilly SM, Moiseyenko, Talbot DC, et al. A randomized phase II study of Xeloda® (capecitabine) vs. paclitaxel in breast cancer patients mailing previous anthracycline therapy. Prc Am Soc Clin Oncol 1998; 17: 163a (Abstract 627).
53. O'Shaughnessy JA, Blum J, Moyseyenko V, et al. Randomized, open- label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methoterxate and 5 fluororuacil) as first line therapy for advanced/metastatic breast cancer. Ann Oncol 2001; 12: 1247-54.
54. Olin JJ, Muss HB. New strategies for managing metastatic breast cancer. Oncology (Huntingt) 2000; 14: 629-41.
55. Balducci L, Corcovan MB. Antineoplastic chemotherapy of the older cancer patint. Hematol Oncol Clin North Am 2000; 14: 193: 212.
56. Stein B, Petrelli NJ, Douglass HO, et al. Age and sex are independent predictors of 5 fluorouracil toxicity: Analysis of a large scale phase III trial. Cancer 1995; 65: 11-7.
57. Jacobson S, Cha S, Sargent D, et al. Tolerability, dose intensity and benefits of 5 FU based chemotherapy for advanced colorectal cancer (CRC) in the elderly: A north Central Cancer Treatment Group (NCCTG) study (abstract). Proc Am Soc Clin Oncol 201; 20: 384a (Abstract 1534).
58. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000; 343: 905-14.
59. Knight RD, Millar L, Elfring G, Pirotta N, Locker P, Saltz L. Evaluation of age, gender, performance status (PS) and organ dysfunction as predictors of toxicity with first line irinotecan, Fluorouracil, leucovorin therapy of metastatic colorectal cancer. Proc Am Soc Cain Oncol 2001; 20; 134a (Abstract 534).
60. Freyer G, Rougier P, Bugat A, et al. Prognostic factors for tumour response, progresion free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second- line chemotherapy after 5 FU failure. Br J Cancer 2000; 83: 431-7.
61. Feliu J, Barón MG, Espinosa E, et al. Urac and tegafur modulated with leucovorin: An effective regimen with low toxicity for the treatment of colorectal carcinoma in the elderly. Cancer 1997; 79: 1884-9.
62. Twelves C. Capecitabine as first line treatment n colorectal cancer; pooled data from two large, phase III trials. Eur J Cancer 2002; 38 (Supl. 2): 15-20.
63. De Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-47.
64. Kerr DJ, Gray R, Mc Conkey C, et al. Adyuvant chemotherapy with 5-fluorouracil, L-folinic acid and levamisole for patients with colorectal cancer: Non randomised comparison of weekly versus tour weekly schedules-less pain, some gain. Ann Oncol 2000; 11: 947-55.
65. Sargent D, Goldberg R, Jacobson D, et al. A pooled analysis of adyuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001; 345: 1091-7.
66. Knight RD, Millar L, Elfring G, Pirotta N, Locker P, Saltz L. Evaluation of age, gender, performance status (PS) and organ dysfunction as predictors of toxicity with first line irinotecan, fluorouracil, leucovorin therapy of metastatic colorectal cancer. Proc Am Soc Clin Oncol 2001; 20: 134a.
67. a ed. Nueva York, NY; Lippincott, Williams and Wilkins; 2000. p. 1071-80.
68. Kelly K, Giarritta S, Hayes S, et al. For the Southwest Oncology Group. Should older patients receive combination chemotherapy for advanced stage non-small cel luna cancer? An analysis of Southwest Oncology Trials 9509 and 9308 (Abstract). Proc Am Soc Clin Oncol 2001; 20: 329a (Abstract 1313).
69. Langer C, Manola J, Bernardo P, Bonomi P, Kugler A, Jognson D. Advanced age alone does not comrpomise outcome in fit non small cell lung cancer patients receiving platinum based therapy implications of EOG5592. Proc Am Soc Clin Oncol 2000; 19: 489a (Abstract 1912).
70. Hensing TA, Socinsky MA, Schell MJ, Lee J. Age dos not alter toxicity or survival for patients with stage IIIB/IV non small cell luna cancer treated with carboplatin and paclitaxel. Proc Am Soc Clin Oncol 2001; 20: 346a (Abstract 1382).
71. The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer. J Natl Cancer Ins 1999; 91: 66-72.
72. Shepherd FA, Abratt, RP, Anderson H, Gatzemeir U, Anglin G, Iglesias J. Gemcitabine in the treatment of elderly patients with advanced non-small cell lung cancer. Semin Oncol 1997; 24 (2 Supl. 7): S7-S55.
73. Gridelli C, Perrone F, Cigolari S, et al. For the Miles Investigators. The MILES (Multicenter Italian Lung Cancer in the Elderly Study) phase 3 trial: Gemcitabine plus vinorelbine vs. vinorelbine and vs. gemcitabine in elderly advanced NSCLC patients (abstract). Proc Am Aoc Clin Oncol 2001; 20: 308a (Abstract 1230).
74. Fidias P, Supko J, Martns R, et al. A phase II clinical and pharmacokinectic study of weekly paclitaxel in elderly patients with non small cell luna cancer. Lung Cancer 2000; 29: 57.
75. Hainsworth JD, Burris HA.
76. Sheperd F, Bezjak A. Treatment of small cell luna cancer in the elderly patient. En: Pass H, Mitchell JB, Johnson DH, Turissi A, Minna JD. Lung Cancer: Principles and Practice, 2° ed. Nueva York, NY; Lippincott Williams and Wilkins; 2000. p. 1081-91.
77. Johnson BE, Argiris A, Downey RJ, et al. Small cell luna cancer: Practice guidelines in oncology. V: 1. 2002.
78. Jernal A, Thomas A, Murria T, Thun M. Cancer statistics, 2002, Ca Cancer J Clin 2002; 52: 23-47.
79. Mc Guire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334; 1-6.
80. Piccart MJ, Bertelsen K, Stuart G, et al. Is cisplatin-paclitaxel the Standard in first linetreatment of advanced ovarian cancer? The EORTC GCCG, NOCOVA, NCI-C and Scottish intergroup experience. Proc Am Soc Clin Oncol 1997; 16: 352a (Abstract 1258).
81. du Bois A, Richter B, Warm M, et al. Cisplatin/paclitaxel vs. carboplatin/pacliaxel as 1st line treatment in ovarian cancer. Proc Am Soc Clin Oncol 1998; 17: 361a (Abstract 1395).
82. Ozols RF, Bundy BN, Fowler J, et al. Randomized phase III study of cisplatin- paclitaxel versus carboplatin-paclitaxel in optimal stage III epithelial ovarian cancer: A Gynecologic Oncology Group trial (GOG 158). Proc Am Soc Clin Oncol 1999; 18: 356a (Abstract 1373).
83. Mirhashemi R, Nieves Neira W, Averette H. Gynecologic malignancies in older women. Oncology (Huntingt) 2001; 15: 580-98.
84. Vercelli M, Quaglia A, Casella C, Parodi S, Capocaccia R, Martínez García. Relative survival in elderly cancer patients in Europe. Eur J Cancer 1998; 34: 2264-70.
85. Sant M, Capocaccia R, Coleman MP, Berrino F, Gatta G, Micheli A, et al. Cancer survival increases in Europe, but international differences remain wide. Eur J Cancer 2001; 37: 1659-67.
86. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive Non-Hodgkin's Lymphoma. N Engl J Med 1993; 329: 987-94.
87. Danieu L, Wong G, Koziner B, Clarkson B. Predictive model for prognosis in advanced diffuse histiocytic lymphoma. Cancer Res 1986; 46: 5372-9.
88. Jagannath S, Velasquez WS, Tucker SL, Manning JT, McLaughlin P, Fuller LM. Stage IV diffuse large-cell lymphoma: A long-term analysis. J Clin Oncol 1985; 3: 39-47.
89. Armitage JO, Potter JF. Aggresive chemotherapy for diffuse histiocytic lymphoma in the elderly: Increased complications with advancing age. J Am Geriatr Soc 1984; 32: 269-73.
90. Hoerni B, Sotto JJ, Eghbali H, Sotto MF, Hoerni-Simon G, Pegourie B. Non-Hodgkin's malignant lymphomas in patients older than 80. 70 cases. Cancer 1988; 61: 2057-9.
91. Gómez H, Hidalgo M, Casanova L, Colomer R, Pen DLK, Otero J, et al. Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin's lymphoma: Results of a multivariate analysis. J Clin Oncol 1998; 16: 2065-9.
92. a Edición. Filadelfia: Lippincott Williams & Wilkins; 2001.
93. Oguchi M, Izuno I, Takei K, Shikama N, Sasaki S, Gomi K, et al. Treatment for non-Hodgkin's lymphoma (stage I, II) of the elderly: Usefulness of local and regional irradiation and reduced dose chemotherapy. Int J Radiat Oncol Biol Phys 1997; 37: 87-92.
94. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mice EM, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphomas. N Engl J Med 1993; 328: 1002-6.
95. Dixon DO, Neilan B, Jones SE, Lipschitz AD, Miller PT, Grozea NP, et al. Effect of age on therapeutic outcome in advanced diffusse histiocytic lymphoma: The Southwest Oncology Group experience. J Clin Oncol 1986; 4: 295-305.
96. O'Reilly SE, Klimo P, Connors JM. Low-dose ACOP-B and VAPE. Weekly chemotherapy for elderly patients with advanced-stage diffuse large-cell lymphoma. J Clin Oncol 1991; 9: 741-7.
97. Kouroukis CT, Browman GP, Esmail R, Meyer RM. Chemotherapy for older patients with newly diagnosed, advanced-stage, aggressive-histology non Hodgkin lymphoma: A systematic review. Ann Intern Med 2002; 136: 136-43.
98. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-42.
99. Flores E, Afonso R. Linfomas de células grandes. En: Pérez Manga G, editores. Oncología Geriátrica. Madrid: Nova Sidonia Oncol 2001: 254-64.
100. Alfonso R, Flores E. Linfomas de Hodgkin en el anciano. En: Pérez-Manga G, editor. Oncología Geriátrica. Madrid: Nova Sidonia Oncología; 2001. p. 229-40.
101. Muss HB. Older age-not a barrier to cancer treatment. N Engl J Med 2001; 345: 1127-8.